Cargando…

Brain–Computer Interface-Controlled Exoskeletons in Clinical Neurorehabilitation: Ready or Not?

The development of brain–computer interface-controlled exoskeletons promises new treatment strategies for neurorehabilitation after stroke or spinal cord injury. By converting brain/neural activity into control signals of wearable actuators, brain/neural exoskeletons (B/NEs) enable the execution of...

Descripción completa

Detalles Bibliográficos
Autores principales: Colucci, Annalisa, Vermehren, Mareike, Cavallo, Alessia, Angerhöfer, Cornelius, Peekhaus, Niels, Zollo, Loredana, Kim, Won-Seok, Paik, Nam-Jong, Soekadar, Surjo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720703/
https://www.ncbi.nlm.nih.gov/pubmed/36426541
http://dx.doi.org/10.1177/15459683221138751
Descripción
Sumario:The development of brain–computer interface-controlled exoskeletons promises new treatment strategies for neurorehabilitation after stroke or spinal cord injury. By converting brain/neural activity into control signals of wearable actuators, brain/neural exoskeletons (B/NEs) enable the execution of movements despite impaired motor function. Beyond the use as assistive devices, it was shown that—upon repeated use over several weeks—B/NEs can trigger motor recovery, even in chronic paralysis. Recent development of lightweight robotic actuators, comfortable and portable real-world brain recordings, as well as reliable brain/neural control strategies have paved the way for B/NEs to enter clinical care. Although B/NEs are now technically ready for broader clinical use, their promotion will critically depend on early adopters, for example, research-oriented physiotherapists or clinicians who are open for innovation. Data collected by early adopters will further elucidate the underlying mechanisms of B/NE-triggered motor recovery and play a key role in increasing efficacy of personalized treatment strategies. Moreover, early adopters will provide indispensable feedback to the manufacturers necessary to further improve robustness, applicability, and adoption of B/NEs into existing therapy plans.